NCT02287428 2026-04-17
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
Clinical Trials
740 trialsNCT05698524 2026-04-17
A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
University of Nebraska
Phase 1 Recruiting
NCT03922555 2026-04-16
ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas
Massachusetts General Hospital
Phase 1 Recruiting
NCT03451799 2026-04-15
Ketogenic Diet in Combination With Standard-of-care Radiation and Temozolomide for Patients With Glioblastoma
Cedars-Sinai Medical Center
Phase 1 Completed
NCT04308330 2026-04-15
NYMC195
New York Medical College
Phase 1 Recruiting
NCT04897321 2026-04-15
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
St. Jude Children's Research Hospital
Phase 1 Recruiting
NCT06126744 2026-04-15
PuMP
Duke University
Phase 1 Recruiting
NCT06666712 2026-04-15
TPT CED rHGG
Columbia University
Phase 1 Recruiting
NCT00083135 2026-04-14
N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Completed
NCT00093353 2026-04-14
N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Completed
NCT00295919 2026-04-14
N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Completed
NCT00509353 2026-04-14
N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Completed
NCT00646230 2026-04-14
IV Fenretinide
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Completed
NCT03911388 2026-04-13
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT04185038 2026-04-13
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
Seattle Children's Hospital
Phase 1 Recruiting
NCT04485559 2026-04-13
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
University of California, San Francisco
Phase 1 Suspended
NCT05168423 2026-04-13
CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM
University of Pennsylvania
Phase 1 Active not recruiting
NCT07134842 2026-04-09
WinGlio-ipi
University College, London
Phase 1 Recruiting
NCT07518654 2026-04-08
ThINKK-01
St. Justine's Hospital
Phase 1 Not yet recruiting
NCT07089641 2026-04-07
ERAS801-SARG
Jonsson Comprehensive Cancer Center
Phase 1 Recruiting
NCT01822652 2026-04-06
GRAIN
Baylor College of Medicine
Phase 1 Active not recruiting
NCT06514898 2026-04-03
MATCHPOINT
University of Florida
Phase 1 Active not recruiting
NCT05789394 2026-04-02
Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy
Mayo Clinic
Phase 1 Recruiting
NCT04197934 2026-03-30
WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases
Mayo Clinic
Phase 1 Active not recruiting
NCT06934889 2026-03-30
Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT03605550 2026-03-27
A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma
Nationwide Children's Hospital
Phase 1 Active not recruiting
NCT03721068 2026-03-27
Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma
UNC Lineberger Comprehensive Cancer Center
Phase 1 Recruiting
NCT03739411 2026-03-27
Hyperpolarized Imaging in Diagnosing Participants With Glioma
University of California, San Francisco
Phase 1 Recruiting
NCT04019002 2026-03-27
Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma
University of California, San Francisco
Phase 1 Completed
NCT05139056 2026-03-27
Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas
City of Hope Medical Center
Phase 1 Suspended
NCT05184816 2026-03-27
A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT07496073 2026-03-27
A Phase I, Single-arm, Open-label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of CHT101 Cell Infusion in Adult Subjects With Recurrent or Progressive Malignant Primary Brain Tumors（CROWN）
Tianjin Medical University Cancer Institute and Hospital
Phase 1 Not yet recruiting
NCT07492316 2026-03-25
PNOC020 rMB
University of Florida
Phase 1 Not yet recruiting
NCT02298348 2026-03-23
N2013-02
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Active not recruiting
NCT02573896 2026-03-23
Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Active not recruiting
NCT02852655 2026-03-20
A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT04573140 2026-03-19
PNOC020
University of Florida
Phase 1 Active not recruiting
NCT07481721 2026-03-19
APIC-RG
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1 Not yet recruiting
NCT02115074 2026-03-18
FLUVABREX
Centre Oscar Lambret
Phase 1 Completed
NCT04119024 2026-03-17
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Phase 1 Recruiting
NCT04732065 2026-03-17
PNOC023
University of California, San Francisco
Phase 1 Recruiting
NCT04943848 2026-03-17
rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
Ann & Robert H Lurie Children's Hospital of Chicago
Phase 1 Recruiting
NCT01165333 2026-03-16
CILENT
Centre Oscar Lambret
Phase 1 Completed
NCT06186401 2026-03-16
Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells
University of California, San Francisco
Phase 1 Recruiting
NCT03749187 2026-03-13
PNOC017
University of California, San Francisco
Phase 1 Active not recruiting
NCT06946680 2026-03-13
IMPACT
University of Florida
Phase 1 Active not recruiting
NCT06502171 2026-03-12
NF113
University of Alabama at Birmingham
Phase 1 Not yet recruiting
NCT05743595 2026-03-11
Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Washington University School of Medicine
Phase 1 Active not recruiting
NCT06914479 2026-03-11
Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors
University of Michigan Rogel Cancer Center
Phase 1 Recruiting
NCT02780128 2026-03-10
NEPENTHE
Children's Hospital of Philadelphia
Phase 1 Terminated